arrow_right
Clinical Validation
CLINICAL VALIDATION
STUDY RESULTS
For intermediate pre-test risk patients with an inconclusive bronchoscopy, Percepta GSC can down-classify the risk of primary lung cancer to low with a 91% NPV to help avoid additional invasive procedures or up-classify the risk to high with a 65% PPV to inform next intervention steps3.
LINK TO STUDY
CONTACT A REP TO ORDER VERACYTE TESTING
Veracyte representatives are happy to assist you and to discuss how to integrate our tests into your practice.
First Name
Last Name
Email
Institution
Zip Code
Which Test Interests You?
More About You
Message
CONTACT REP
R E F E R E N C E S 
3. Bhorade S et al. Accuracy of the Next Generation Percepta Genomic Sequencing
Classifier (GSC) for the Diagnosis of Suspicious Indeterminant Pulmonary Nodules. Poster presented
at: Second Conference of the AABIP; August 15-17, 2019; Denver, CO.
© 2020 Veracyte, Inc. All rights reserved.